1. Home
  2. BNKK vs SCYX Comparison

BNKK vs SCYX Comparison

Compare BNKK & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bonk Inc.

BNKK

Bonk Inc.

N/A

Current Price

$3.90

Market Cap

24.9M

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.80

Market Cap

29.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNKK
SCYX
Founded
2018
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.9M
29.8M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
BNKK
SCYX
Price
$3.90
$0.80
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
4.0M
534.5K
Earning Date
03-27-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,293,124.00
$2,932,000.00
Revenue This Year
N/A
$170.77
Revenue Next Year
N/A
$286.38
P/E Ratio
N/A
N/A
Revenue Growth
251.44
N/A
52 Week Low
$2.33
$0.57
52 Week High
$46.90
$1.31

Technical Indicators

Market Signals
Indicator
BNKK
SCYX
Relative Strength Index (RSI) 50.31 62.99
Support Level $3.45 $0.69
Resistance Level $4.14 $0.78
Average True Range (ATR) 0.67 0.07
MACD -0.15 0.00
Stochastic Oscillator 8.33 68.24

Price Performance

Historical Comparison
BNKK
SCYX

About BNKK Bonk Inc.

Bonk Inc is a publicly traded company focused on building a digital asset treasury centered around the BONK ecosystem on the Solana blockchain. It generates revenue through a recurring interest in the memecoin launchpad letsBONK.fun and actively manages its treasury of BONK tokens.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: